Wissenschaftliche Poster

ASH Annual Meeting 2022

HDP-101, an Anti-BCMA Antibody-Drug Conjugate with a Novel Payload Amanitin in Patients with Relapsed Multiple Myeloma, Initial Findings of the First in Human Study

AACR Annual Meeting 2022

Treatment with ATAC® induces tolerability in preclinical animal models without triggering tolerance

AACR Annual Meeting 2022

ATACs® induce immunogenic cell death and improve the efficacy of immune checkpoint inhibitors

AACR Annual Meeting 2021

Combination of ATACs with Immune checkpoint inhibitors shows synergistic therapeutic effect

AACR Annual Meeting 2021

Preclinical evaluation of anti-CD37 Antibody-Targeted Amanitin Conjugates (ATAC) in B-cell malignancies

AACR Annual Meeting 2021

Amanitin-based ADCs targeting PSMA as novel therapeutic modality for prostate cancer therapy

© Heidelberg Pharma AG. All rights reserved.